Sistema de Salut de Catalunya
Institut Català de la Salut
[Amaral T] Center for Dermato-oncology, Department of Dermatology, Eberhard Karls University of Tübingen, Tübingen, Germany. Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Tübingen, Germany. [Nanz L] Center for Dermato-oncology, Department of Dermatology, Eberhard Karls University of Tübingen, Tübingen, Germany. [Serna Higuita LM] Clinical Epidemiology and Applied Biostatistics, Eberhard Karls University of Tübingen, Tübingen, Germany. [Ascierto P] Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Instituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. [Berking C] Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Deutsches Zentrum Immuntherapie and Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuernberg, (CCC ER-EMN), Erlangen, Germany. [Muñoz Couselo E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-03-11T11:16:39Z
2025-03-11T11:16:39Z
2024
2025-01
Checkpoint inhibitors; Overall survival; Targeted therapy
Inhibidores de puntos de control; Supervivencia global; Terapia dirigida
Inhibidors de punts de control; supervivència global; Teràpia dirigida
Background Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting. However, for patients with a BRAF V600 mutation, the optimal adjuvant therapy remains unclear due to the lack of head-to-head comparison studies. Methods We conducted a systematic review of real-world data on adjuvant therapy in stage III melanoma to determine the best option for patients with BRAF V600 mutations. Kaplan-Meier curves were generated for TT and ICI using Digitizelt software. Results Nine publications with 3625 patients were included. TT showed better relapse-free survival (RFS) at 6, 12, 24, and 36 months than ICI. A similar trend was observed for distant metastasis-free survival (DMFS), with no apparent difference in overall survival. Conclusion Real-world data suggest that adjuvant TT may be associated with better RFS and DMFS in stage III BRAF V600-mutated melanoma compared to ICI.
Article
Published version
English
Anomalies cromosòmiques; Melanoma - Immunoteràpia; Pell - Càncer - Immunoteràpia; Medicaments antineoplàstics - Ús terapèutic; Avaluació de resultats (Assistència sanitària); PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Molecular Targeted Therapy; DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms::Neoplasms by Histologic Type::Neoplasms::Neoplasms by Histologic Type::Nevi and Melanomas::Melanoma; Other subheadings::Other subheadings::Other subheadings::/drug therapy; DISEASES::Neoplasms::Neoplasms by Site::Skin Neoplasms; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Progression-Free Survival; FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::terapia molecular selectiva; ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias::neoplasias por tipo histológico::neoplasias::neoplasias por tipo histológico::nevos y melanomas::melanoma; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias cutáneas; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::estadística como asunto::análisis de supervivencia::supervivencia libre de progresión
Elsevier
European Journal of Cancer;215
https://doi.org/10.1016/j.ejca.2024.115160
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]
